A Randomized Open-label Study of 400 mg Versus 800 mg of Imatinib Mesylate in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints.
This study investigated the safety and efficacy of 400mg Versus 800mg imatinib in patients
with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase
(CML-CP) using molecular endpoints.
Study Status: Terminated
Leukemia, Myeloid, Chronic Phase
Drug: Imatinib mesylate
Information provided by:
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Foundation
Cleveland, Ohio 44195
Novartis Pharmaceuticals., Study Director